Podcast appearances, conference keynotes, panels, press interviews. Clinical data integrity, sponsor accountability, vendor governance, and the regulatory shift sponsors are navigating under ICH GCP E6(R3), EMA guidelines, and FDA 21 CFR Part 11.
The data behind Lauren’s keynotes
What hosts, conference programmers, and journalists tend to say about putting Lauren on their stage, panel, or show.
Lauren writes and speaks from the sponsor’s accountability seat. The perspective is independent of CRO delivery and independent of vendor commercial interest. Useful for audiences who want clarity on who actually owns clinical data integrity, and who is exposed when it falters.
Every perspective is anchored in ICH GCP E6(R3), EMA guidelines, FDA 21 CFR Part 11, and ALCOA+ principles. Lauren chaired the ACDM eDigital Data Management Expert Group for five years and co-authored four ACDM industry whitepapers. The references are operational, not theoretical.
Lauren prepares with the host or organiser before the recording or the keynote. She arrives with specific, publishable insight, never with quotable hot takes. Her diplomatic questioning method exposes assumptions without combativeness; it does not score points.
Why the MSA does not transfer regulatory accountability, and what evidence sponsors need at inspection.
Read more →The structural gap between regulator expectations and vendor accountability, and how sponsors close it.
Read more →Why selecting clinical technology before defining trial-level requirements is a procurement risk.
Read more →Reframing data integrity from regulatory hygiene to enterprise risk, with examples from sponsor-side practice.
Read more →The sponsor signed the protocol. The sponsor owns the data. No master service agreement transfers that.Foundational perspective · The Ecosystem View
You can delegate tasks. You cannot delegate responsibility.i. · Accountability Cannot Be Delegated
Regulators set expectations vendors are not directly accountable for. Sponsors absorb the gap by default.ii. · The Regulator-Vendor Gap
Define trial-level requirements before selecting clinical technology. Selection without specification is a procurement risk.iii. · Requirements Before Selection
Data integrity is not regulatory hygiene. It is enterprise risk that touches asset valuation directly.iv. · Data Integrity Is a Commercial Risk
Innovation is welcome. Only when it is validated.Lauren’s operating principle
ArkFest 2025 is Arkivum's free, online digital-archiving-and-preservation conference (15–17 July 2025) for professionals in pharma, higher education, and cultural heritage. Lauren appears on the speakers…
Welcome to Trail Blazers latest episode, where we delve into the fascinating and complex world of clinical research, exploring how innovative technologies are revolutionising the…
Compliance, data integrity and operational efficiency in pharma
YouTube replay of the DiMe webinar where Lauren served as a biotech digital-innovation panellist. The video is publicly hosted and linked from the DiMe webinar…
DiMe's official webinar landing page for the 28 January 2025 panel on biotech adoption of digital endpoints. The page hosts the recording, slides, and panellist/moderator…
Tell me the topic, audience, and timing. If we are a fit, my team will reply within two business days. If not, my team will say so directly. Reflective conversations beat rushed ones.
Podcasts: typically 3 to 4 weeks lead time. Conference keynotes and panels: 8 to 12 weeks ideally, longer for headline slots. Press interviews on topical stories are often faster turnaround. Roundtables and webinars sit between the two. Lauren is currently accepting Q2 2026 speaking; ARKFest 2026 is a confirmed return engagement.
Fees depend on event type, audience, format, and whether the programming is sponsored. Some engagements are unpaid when the audience fit is strong (academic, regulatory, or peer-association events, for example). Industry events with vendor sponsorship typically include a fee. Include budget context in your request and Gina Dunn will reply with whether the fit is right.
Lauren has stated authority boundaries. Out of scope: AI implementation specifics or technical AI advice; deep IT infrastructure standards; individual vendor critique or named-vendor commentary; medical advice, clinical recommendations, or patient-level guidance; forward-looking statements about specific assets, products, or indications; interpretation of unpublished or confidential clinical data; vendor rankings or competitive CRO comparisons.
Yes. Lauren is UK-based and travels internationally for industry events, regulatory roundtables, and sponsor-side advisory days. Remote and virtual appearances are supported and often preferred for podcasts and panel discussions.
Conference keynotes (preferred 30 to 45 minute slots), panel chairs and panellist roles, podcast guest interviews (60 to 90 minute long-form preferred over 20 minute soundbite formats), regulatory roundtables and closed-door advisory sessions, press interviews and bylined commentary, sponsor-side workshops on clinical systems oversight and inspection readiness.
No. Sponsor engagements are confidential by default. Examples Lauren uses on stage and in press are generalised structural patterns drawn from years of sponsor-side observation, never case studies of specific clients. Where regulatory references are made (ICH GCP E6(R3), EMA, FDA 21 CFR Part 11, ALCOA+), readers and audiences are encouraged to consult the primary source for authoritative content.
For press enquiries, podcast bookings, speaking invitations, and interview requests on Lauren’s behalf. Responses within two business days.
Lauren does not handle outbound bookings directly. Send everything to Gina; it will reach Lauren if it should.